BioCentury | Oct 31, 2011
Finance

Morgenthaler splits

Morgenthaler splits The life sciences team of Morgenthaler Ventures is leaving to join Advanced Technology Ventures . The move has been disclosed to LPs, and the teams are in the process of joint fundraising, according to...
BC Week In Review | Dec 13, 2010
Clinical News

Symplicity Catheter System: Phase II data

The ongoing, open-label, international Phase II Symplicity HTN-2 trial in 106 patients with uncontrolled hypertension showed that Ardian's Symplicity Catheter System plus patients' existing anti-hypertensive medications met the primary endpoint of significantly reducing blood pressure...
BC Week In Review | Dec 6, 2010
Company News

Ardian, Medtronic deal

Medtronic will acquire the 89% of Ardian it does not already own for $800 million in cash up front. Ardian also will be eligible to receive milestones equal to the annual revenue growth associated with...
BioCentury | Dec 6, 2010
Finance

Devices target drug space

Morgenthaler Ventures' strategy of targeting ill-served major therapeutic markets with medical device alternatives paid off last month, with the sale of hypertension device play Ardian Inc. to Medtronic Inc. (NYSE:MDT) for $800 million plus commercial...
BC Extra | Nov 24, 2010
Company News

Medtronic to acquire Ardian

Medtronic Inc. (NYSE:MDT) will acquire the 89% of Ardian Inc. (Mountain View, Calif.) it does not already own for $800 million in cash up front. Ardian also will be eligible to receive milestones equal to...
BC Week In Review | Apr 6, 2009
Clinical News

Symplicity Catheter System: Phase I data

Data from an open-label, Australian and European Phase I trial in 50 patients showed that the Symplicity Catheter System was safe and produced significant blood pressure reductions of 21/10, 22/11, 24/11 and 27/17 mmHg at...
Items per page:
1 - 6 of 6
BioCentury | Oct 31, 2011
Finance

Morgenthaler splits

Morgenthaler splits The life sciences team of Morgenthaler Ventures is leaving to join Advanced Technology Ventures . The move has been disclosed to LPs, and the teams are in the process of joint fundraising, according to...
BC Week In Review | Dec 13, 2010
Clinical News

Symplicity Catheter System: Phase II data

The ongoing, open-label, international Phase II Symplicity HTN-2 trial in 106 patients with uncontrolled hypertension showed that Ardian's Symplicity Catheter System plus patients' existing anti-hypertensive medications met the primary endpoint of significantly reducing blood pressure...
BC Week In Review | Dec 6, 2010
Company News

Ardian, Medtronic deal

Medtronic will acquire the 89% of Ardian it does not already own for $800 million in cash up front. Ardian also will be eligible to receive milestones equal to the annual revenue growth associated with...
BioCentury | Dec 6, 2010
Finance

Devices target drug space

Morgenthaler Ventures' strategy of targeting ill-served major therapeutic markets with medical device alternatives paid off last month, with the sale of hypertension device play Ardian Inc. to Medtronic Inc. (NYSE:MDT) for $800 million plus commercial...
BC Extra | Nov 24, 2010
Company News

Medtronic to acquire Ardian

Medtronic Inc. (NYSE:MDT) will acquire the 89% of Ardian Inc. (Mountain View, Calif.) it does not already own for $800 million in cash up front. Ardian also will be eligible to receive milestones equal to...
BC Week In Review | Apr 6, 2009
Clinical News

Symplicity Catheter System: Phase I data

Data from an open-label, Australian and European Phase I trial in 50 patients showed that the Symplicity Catheter System was safe and produced significant blood pressure reductions of 21/10, 22/11, 24/11 and 27/17 mmHg at...
Items per page:
1 - 6 of 6